New package labeling for NovoLog Mix 70/30 and NovoLog
From the October 2005 issue
 Novo Nordisk Inc. and FDA recently announced that package labeling changes were implemented to help prevent product selection mix-ups between NOVOLOG MIX 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) and NOVOLOG (insulin aspart [rDNA origin] injection). Previous packaging for both product lines was very similar, using a white background with a blue band. The new packaging for NovoLog Mix 70/30 products retains a similar design using a white background with a blue band, but the new packaging for NovoLog products utilizes a white background with an orange band (see photo).
Although color differentiation can help with product recognition, it should not be relied on as the sole means of identification. Practitioners should also use the product name and NDC number to distinguish insulin formulations. Keep in mind that this recent packaging change will not help to prevent name confusion errors involving these two products or other Novo insulin products (i.e., NovoLog Mix 70/30 and NOVOLIN 70/30 or NovoLog and NOVOLIN ) that may occur during prescribing, prescription interpretation, and order entry. To view the FDA alert, go to http://www.ismp.org/MSAarticles/fdasafetyalerts.htm
|
